FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Al-Siddiq Waqaas
2. Issuer Name and Ticker or Trading Symbol

BIOTRICITY INC. [ BTCY ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO and President
(Last)          (First)          (Middle)

275 SHORELINE DRIVE, SUITE 150
3. Date of Earliest Transaction (MM/DD/YYYY)

4/7/2020
(Street)

REDWOOD CITY, CA 94065
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

4/9/2020 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to purchase) $1.06 4/7/2020  A   1400000     (1)4/7/2025 Common Stock 1400000 $0 1400000 D  

Explanation of Responses:
(1) The options vest quarterly over four years.

Remarks:
The Amended Form 4 is being filed to correct the expiration date and exercise price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Al-Siddiq Waqaas
275 SHORELINE DRIVE, SUITE 150
REDWOOD CITY, CA 94065
XXCEO and President

Signatures
/s/ Waqaas Al-Siddiq6/3/2020
**Signature of Reporting PersonDate

Biotricity (QB) (USOTC:BTCY)
過去 株価チャート
から 10 2024 まで 11 2024 Biotricity (QB)のチャートをもっと見るにはこちらをクリック
Biotricity (QB) (USOTC:BTCY)
過去 株価チャート
から 11 2023 まで 11 2024 Biotricity (QB)のチャートをもっと見るにはこちらをクリック